Skip to main content

Polsky Bruce's Form 4 filing

Atea Pharmaceuticals, Inc.AVIR · filed Nov 18, 2026

Accession no.
0001193125-26-467490
Filed
Nov 18, 2026, 8:59 PM ET
Trade date
Nov 16-18, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $168.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Polsky BruceCIK 0001508458Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 16, 2026Common StockMOption exerciseAcquired+48,028$1.24+$59,554.72172,834Direct
Nov 16, 2026Common StockSSaleDisposed−14,254$4.27F1−$60,840.35158,580Direct
Nov 17, 2026Common StockMOption exerciseAcquired+8,720$1.24+$10,812.8167,300Direct
Nov 17, 2026Common StockSSaleDisposed−8,720$4.03F2−$35,155.55158,580Direct
Nov 18, 2026Common StockMOption exerciseAcquired+18,252$1.24+$22,632.48176,832Direct
Nov 18, 2026Common StockSSaleDisposed−18,252$3.95F3−$72,099.05158,580Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 16, 2026Common StockMOption exerciseDisposed−48,028$0.00$026,972Direct
Nov 17, 2026Common StockMOption exerciseDisposed−8,720$0.00$018,252Direct
Nov 18, 2026Common StockMOption exerciseDisposed−18,252$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.20 to $4.33. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $4.00. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Remarks

All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

Read the full filing on SEC EDGAR (opens in a new tab)